May 1 |
Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities
|
May 1 |
Emergent Biosolutions Non-GAAP EPS of $0.59 beats by $1.45, revenue of $300.4M beats by $75.9M
|
May 1 |
Emergent BioSolutions Reports First Quarter 2024 Financial Results
|
May 1 |
Emergent BioSolutions to lay off about 300 employees
|
May 1 |
UPDATE 2-Emergent BioSolutions to lay off about 300 employees
|
May 1 |
Emergent BioSolutions announces reduction of about 300 employees
|
May 1 |
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
|
May 1 |
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
|
Apr 30 |
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
|
Apr 30 |
Emergent Biosolutions Q1 2024 Earnings Preview
|